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Abstract
Background: Lysosomal a-mannosidase is an enzyme that acts to degrade N-linked
oligosaccharides and hence plays an important role in mannose metabolism in humans and other
mammalian species, especially livestock. Mutations in the gene (MAN2B1) encoding lysosomal a-D-
mannosidase cause improper coding, resulting in dysfunctional or non-functional protein, causing
the disease a-mannosidosis. Mapping disease mutations to the structure of the protein can help in
understanding the functional consequences of these mutations and thus indirectly, the finer aspects
of the pathology and clinical manifestations of the disease, including phenotypic severity as a
function of the genotype.
Results: A comprehensive homology modeling study of all the wild-type and inherited mutations
of lysosomal a-mannosidase in four different species, human, cow, cat and guinea pig, reveals a
significant correlation between the severity of the genotype and the phenotype in a-mannosidosis.
We used the X-ray crystallographic structure of bovine lysosomal a-mannosidase as template,
containing only two disulphide bonds and some ligands, to build structural models of wild-type
structures with four disulfide linkages and all bound ligands. These wild-type models were then
used as templates for disease mutations. All the truncations and substitutions involving the residues
in and around the active site and those that destabilize the fold led to severe genotypes resulting in
lethal phenotypes, whereas the mutations lying away from the active site were milder in both their
genotypic and phenotypic expression.
Conclusion: Based on the co-location of mutations from different organisms and their proximity
to the enzyme active site, we have extrapolated observed mutations from one species to
homologous positions in other organisms, as a predictive approach for detecting likely a-
mannosidosis. Besides predicting new disease mutations, this approach also provides a way for
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Open Accessdetecting mutation hotspots in the gene, where novel mutations could be implicated in disease. The
current study has identified five mutational hot-spot regions along the MAN2B1 gene. Structural
mapping can thus provide a rational approach for predicting the phenotype of a disease, based on
observed genotypic variations.
Background
a-D-mannosidase is a lysosomal enzyme which is involved
in the catabolism of N-linked glycoproteins through the
sequential degradation of high-mannose, hybrid and
complex oligosaccharides [1]. The deficiency of this
enzyme results in a recessively inherited lysosomal storage
disease, called a-mannosidosis, which has been observed
in different species in the animals, including domestic cows
(Bos taurus), cats (Felis catus), guinea pigs (Cavia porcellus),
sheep (Ovis aries) and in humans (Homo sapiens). It was
first characterized in humans by Oeckermann in 1967 [2].
Mutations in the MAN2B1 gene, located on chromosome
19 (19 p13.2-q12), encoding lysosomal a-D-mannosidase
cause improper coding resulting in dysfunctional or non-
functional protein and hence causing the disease. Char-
acterized by immune deficiency, facial and skeletal
abnormalities, hearing impairment, and intellectual dis-
ability, a-mannosidosis occurs in 1 of 500,000 live births
[2]. However, clinicians, geneticists and molecular biolo-
gists have not been able to correlate the genotypic
mutations with the observed phenotype [2].
Mapping disease mutations to the structure of a protein
can help in understanding the finer aspects of the
pathology and clinical manifestations of a disease.
Although restricted to diseases where the protein concerned
has a known 3-D structure, such an approach is adequately
detailed at the molecular level to provide rational
explanation for the pathological role of mutations, using
protein 3D structure (SOX9 [3]; human factor H [4,5]).
Therefore, we have attempted a structural bioinformatics
approach to understand the role of the different mutations
causing a-mannosidosis with differing phenotypes.
From OMIM (Online Mendelian Inheritance in Man) [6],
OMIA (Online Mendelian Inheritance in Animals) [7] and
published literature [8], a list of inherited mutations for a-
mannosidosis has been identified. Various mutations like
missense, nonsense, insertions, deletions and also some
splicing mutations have been described in the four species to
date. Of these only the missense mutations result in a
substitution in the protein sequence and were modeled to
study their effect on the phenotype. All the other mutations
result in the truncation of the protein and its improper
function.
An X-ray crystal structure for bovine lysosomal a-D-man-
nosidase [9] (PDB ID: 1O7D), solved at a reasonably
good resolution of 2.7 Å, is available, albeit lacking two
vital disulfide bonds, that hold the five protein chains
of the mature a-D-mannosidase protein together, as
well as nine of the 20 ligands and a few structurally and
functionally important residues. To overcome the
limitations of the available 3D structure, we have
used homology modeling approaches to reconstruct the
complete lysosomal a-D-mannosidase for human,
bovine, cat and guinea pig, to which structures we
have then mapped all known mutations. The trunca-
tion mutations, with the exception of a single trunca-
tion in cat, were not modeled, as most of them
produced proteins spanning less than two of the five
protein chains, leading to a completely compromised
active site.
Our comprehensive analysis, taking into account all
non-splicing mutations (see Additional file 1: table S1)
known to cause a-mannosidosis, reveals a strict geno-
type-phenotype correlation, contrary to the reports of
Malm and Nilssen [2] and Lyons et al. [8]. This disease
can be comparatively well studied as it occurs in different
species, providing us with an evolutionary basis for the
conserved regions of the protein sequence, as well as
active site conservation, where mutations could result in
disastrous consequences. Regions with several mutations
represent hot-spots where novel mutations could lead to
disease. Based on the location of these hot-spots vis-à-vis
the active site of the protein, it is also possible to predict
the disease phenotype: mild, moderate or severe,
extrapolating from known mutations and disease phe-
notypes. In this paper, we describe a prototype structural
bioinformatics analysis method applied to a-mannosi-
dosis, which can be extended to several other diseases for
predicting novel disease phenotypes and for developing
therapies as well as designing drug/inhibitor molecules.
Materials and methods
Observations that the structure of proteins is better
preserved during evolution than their sequence, have
lead to homology modeling [10,11] as an reliable
methodology for generating 3D structural models of
proteins, when the structure of a homologue is available.
The most critical step in modeling a correct structure is
the alignment of the target sequence with that of the
template structure. 3D models of the complete mature
wild-type (WT) bovine a-D-mannosidase protein were
BMC Genomics 2009, 10(Suppl 3):S33 http://www.biomedcentral.com/1471-2164/10/S3/S33
Page 2 of 10
(page number not for citation purposes)developed and put through a series of checks for
structural verification and analysis to select the best
structural model. From this bovine model structure,
homology models were constructed for the WT proteins
for the other species.
Sequence retrieval
Four complete WT lysosomal a-mannosidase amino acid
sequences were retrieved from the Swiss-Prot database
[12], one each, for bovine (Accession No: Q29451),
human (Accession No: O00754), guinea pig (Accession
No: Q8VHC8) and cat (Accession No: O46432).
Sequence alignment
Full-length WT protein sequences, spanning all five protein
chains, were aligned to the sequence corresponding to the
PDB structure, 1O7D, using ClustalX [13] with default
BLOSUM scoringmatrices. As the signal peptide (consisting
of about 50 N-terminal amino acids) is not present in the
matureprotein,thesewereremovedfromtheWTsequences,
prior toalignment. Thegaps inthe alignment were carefully
scrutinized and edited manually to preserve chain bound-
aries and the conservation of structurally and functionally
important residues, especially in view of the large segments
of residues missing in the PDB structure, 1O7D.
Molecular modeling
Since a-D-mannosidase is cleaved into five chains, which
assemble into a functional enzyme, MODELLER 7V7
[14] proved to be the only homology modeling program
allowing multiple chain modeling with ligand inclusion.
The models are constructed by optimally satisfying
spatial constraints and dihedral angle restraints derived
from the alignment of the template structure with the
target sequence [15] and from the CHARMM-22 [16]
force field which together enforce proper stereochem-
istry. Three structural models were generated for each WT
and mutated sequence. The model with the lowest
current energy and objective function was selected for
analysis after carrying out quality assessment and
structural refinement.
A flowchart of the three-step procedure, each involving
various sub-steps, used in this study is depicted in
Figure 1. Swiss-Prot has annotated the existence of four
disulfide bridges and 11 ligands. However, the template
structure contains only two disulfide bridges and 11
ligands, respectively. We have now rebuilt the two
missing disulfide bridges along with all the existing
ligands (shown in Figure 2) in our mannosidase models
in order to analyze the effect of the observed mutations
on all four disulfide bridges and binding of the 11
ligands. The positions of these 11 ligands were extra-
polated from the template structure into all the structural
models using MODELLER. After high-quality WT struc-
tural models for all four species were generated, they
were used as templates to build models corresponding to
all the substitution mutations in three of the species
(bovine, human and guinea pig). The feline mutation
results in a truncation at codon 645 of the MAN2B1
gene, translating which we obtained the protein
sequence, selecting the frame with methionine as the
first residue, for model building.
Swiss-Prot also classified a potential pro-peptide (591-
621) within the bovine WT a-D-mannosidase sequence.
These residues were found to be present in the template
structure (1O7D) and the WEBLOGO [17] representa-
tion of alignment of the six mammalian lysosomal a-
mannosidase sequences (Figure 3) shows this region to
be fairly well conserved. Hence, the putative pro-peptide
region was retained in all the structural models. The
template structure contained 39 water molecules, mostly
present on the surface as water molecules of crystal-
lization. Of the internal water molecules, none were
within 4 Å of the Zn and Tris ligands and thus were
unlikely to be functionally critical. All water molecules
were therefore removed from the template structure and
were excluded from this analysis.
Figure 1
Flowchart of the three-step modeling procedure
used in this study. The three main steps involved in
building a structural model are described, with reference to
query sequence, template sequences and template structure.
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Structural model of wild-type bovine a-mannosidase. The structure is shown in Ca trace representation (in grey) with
chains B and E highlighted in magenta and gold respectively. The bound ligands present in the template structure are shown as
green spheres. Disulfide bonds in the template structure are in yellow ball-and-stick representation, with new disulfide bonds
in the model in red.
Figure 3
WEBLOGO alignment of putative MAN2B1 pro-peptide sequences from six mammalian species. The alignment
represents sequences from human, bovine, cat and guinea pig, along with two other mammalian species, mouse and macaque.
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The quality of each structural model was evaluated using
the three major structural assessment tools, PROCHECK
[19], WHAT IF [20] and PROVE [21], which together
perform checks on stereo-chemical quality, residue
geometry, bond-angle, bond-length and volumetric
analysis. These three programs are available as part of
the Biotech Validation Suite for Protein Structures.
Results and discussion
Assessment of the WT structural models
MODELLER generates structural models from a pool of
randomized potential starting conformations, resulting
from multiple iterations of stereo-chemical refinements.
The structural quality of the final models was assessed
using the Biotech Validation Suite for Protein Structures
as described earlier. Table 1 summarizes the results of
various quality checks that were performed on the WT
models, namely Bwt, Hwt, Gwt and Fwt, for bovine,
human, guinea pig and cat sequences, respectively. All
models have an RMSD score between 0.643-0.894 Å
which is considered excellent for homology models. The
WHATIF Z-score (1.310-1.500) for all the models was
also better than the default of 1.55 for a high-quality
structure, and the PROVE Z-score average (from -0.04 to
0.08) is well within -0.10 to 0.10 for a well-resolved
structure. Most importantly, all the WT models had
98.2% - 98.9% of all their residues in conformationally
permitted regions as predicted by PROCHECK, with 85%
being the minimum requirement for high-resolution
X-ray crystallographic structures. The high degree of
similarity between the target sequences and the template
along with strict modeling protocols adopted in this
study, have contributed to the generation of high quality
WT models.
Mapping mutations to WT structural models
We have primarily constructed a mutation map, by
mapping available mutations in the context of the
enzyme active site to the structural models of a-
mannosidase, based on multiple sequence alignment
of all WT sequences and the sequence of the 1O7D
structure (not shown), to understand where the observed
mutations occur (Figure 4 shows the bovine model). We
note that most of the mutations with lethal phenotypes
are located in and around the active site, thereby
affecting the functionality of the enzyme. Based on the
analysis of structural models, we have correlated the
position and functional consequence of each mutation
to the observed phenotypic consequence. Table 2
suggests that the mutations close to active site have a
direct effect on the enzymatic function of the protein
leading to lethal phenotypes. Where as mutations which
act to destabilize the fold, in turn, affect the active site,
thereby resulting in harmful disease phenotypes. Muta-
tions distant to the active site cause minimal or no
damage to the structure and function of the enzyme,
resulting in mild or viable genotypes and phenotypes.
These three phenotypes correspond to Type 3, Type 2
and Type 1 clinical phenotypes described by Malm and
Nilssen [2].
Table 1: Structural quality assessment for the wild-type models
Models PROVE PROCHECK WHATIF RMSD (Å)
Z-Score average Residues in most favoured regions Residues in
allowed regions
Z-Score
Bwt 0.08 89.9% 8.8% 1.31 0.70
Hwt -0.04 89.1% 9.7% 1.34 0.64
Gwt 0.05 86.7% 11.5% 1.50 0.89
Fwt 0.05 89.0% 9.9% 1.40 0.71
Figure 4
Structural model of WT bovine a-mannosidase
showing the location of all mutations studied in
different species. The spheres denote positions of
truncation mutations. Amino acids involved in substitution
mutations are shown in stick representation. The catalytic
zinc ion is shown as a blue sphere. Mutations are coloured
red, green and orange, representing harmful, viable and mild
phenotypes, respectively.
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Two mutations (R220H and F320L in Table 2) have been
reported to cause fairly severe a-mannosidosis in cattle
[22]. R220H (Figure 4) is due to a G<A change in the
nucleotide sequence at position 662. It reduces the
enzyme activity to 2% [22] by affecting the orientation
and stability of the catalytic nucleophile (D196) [23]
causing impaired substrate binding. Analysis of our
structural model confirms the hypothesis that the
mechanism of inactivation by this mutation may affect
both substrate binding and its hydrolysis, as H220 can
form a hydrogen bond with D196 and Y380 but not with
the Tris ligand (1H 2-amino-2-hydroxymethyl-propane-
1,3-diol) or the substrate, unlike the WT R220 (Figure 5).
F320L (Figure 4) is responsible for reducing a-manno-
sidase activity in the liver of affected cattle to 0.3% [22].
Figure 5 shows how chain A could be anchored in its
current position by an aromatic interaction between the
F320 and the nearby Y84 [9,24]. As both residues are on
the same chain, this does not inhibit the assembly of the
five chain enzyme. However, in the F320L mutant, the
non-aromatic leucine residue destroys the ring-stacking
interaction between the aromatic side-chains F320 and
Y84 in the WT enzyme, thereby destabilizing the 3D
structure of the enzyme.
On the whole, 13 substitution mutations have been
c h a r a c t e r i z e dt oc a u s ea-mannosidosis in humans with
experimentally verified loss in enzyme activity. H200N
[25] and H72L [26] disrupt the active site, while E402K
[26] and S453Y [27] lead to disruption of the ionic
linkages with the surrounding charged residues that
would otherwise stabilize the protein structure. H72L
disturbs a metal-coordinating residue (Figure 5). H200N
alters substrate binding and other catalytic properties of
the enzyme resulting in no residual enzyme activity.
T355P and P356R [26,28] are located in first a-helix of
Table 2: Correlation of the effect of substitution mutations on folding and observed disease phenotype. Mutations leading to severe
phenotypes are highlighted in bold font. AS: Active site
S. No Species Mutated residues Structural location Effect on Structure Phenotypic
effect
1. Human H72L [25] In AS Disrupts AS Lethal
(Type 3)
H200N [24], T355P [25],
P356R [25,27],
E402K [25], S453Y [26]
Close to AS Destabilizes the fold Harmful
(Type 2)
W714R [25], R750W [25,27],
G801D [28], L809P [25]
Away from AS Minor
perturbation
Mild
or Viable
(Type 1)
2. Bovine R220H [21] In AS Disrupts AS Lethal
(Type 3)
F320L [21] Close to AS Destabilizes the fold Harmful
(Type 2)
3. Guinea pig R227W [29] Close to AS Destabilizes the fold Harmful
(Type 2)
Figure 5
Part of the enzyme active site, with a high
concentration of mutations leading to lethal
phenotypes. Several aromatic residues surround the active
site and potentially are involved in binding of the Tris ligand.
Tris (white) is held in position by the catalytic nucleophile,
D196 (blue) via a zinc ion (orange). R220 (green) is directly
involved in ligand binding, along with H72 (purple) and Y380
(magenta). The aromatic side chains of F320 (red) and Y84
(yellow) interact to hold the structure together. These
interactions are shown in dotted lines.
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the initiation of the helix and thus are likely to disturb
the folding of active-site domain. W714R, L809P,
R750W [26,28] and G801D [29] are located in chain
D, where they perturb the structure of the enzyme
minimally and result in mild/viable phenotypes. L518P
and R916S [25] are considered the only exception to our
correlation, as they lie away from the active site yet
potentially disturb the interaction of small E domain
(Figure 2) with active site domain. R916S also damages
the hydrogen bonding between R916 and D170. These
mutations result in a moderately harmful phenotype.
R227W in guinea pigs is due to T<C change in the
nucleotide sequence at position 679 causing significant
loss in enzyme activity [30]. R227 is a structurally and
functionally important conserved residue in all the
species and its substitution could affect ligand binding.
Truncations
Truncations in the human enzyme are due to three
different mutation classes, called non-sense mutations,
insertions and deletions [26]. They result in proteins
with two or three peptide chains (Figure 6), instead of
five chains in the WT protein, causing severe damage to
the viability of the enzyme to assemble into a functional
protein, leading to fatal phenotypes. However, a few
truncations lead to viable genotypes with mild pheno-
types, as they are located far from the active site (in
chains D and E). The feline truncation, 1748del4,
represents a 4-base deletion spanning nucleotide posi-
tions 1749-1752 of the MAN2B1 gene (Figure 6). This
causes termination at codon 645 resulting in a truncated
protein with only three full-length chains, resulting
in impaired binding of the Tris ligand and exhibiting
av e r ys e v e r ep h e n o t y p ei nc a t s( e s p e c i a l l yi nP e r s i a n
cats) [31].
Prediction of potentially harmful mutations
a-mannosidase has a highly conserved sequence across
all species with minor changes to suit the metabolic
requirements. As seen in Figure 7, almost all the mutated
residues causing fatal/harmful phenotypes are highly
conserved, with E53 prevalent in three of the four species
studied and replaced by K53 in the bovine sequence.
Based on our analysis, the residues H72, E402, H200,
S453, T355 and P356, which when substituted cause
extremely fatal forms of a-mannosidosis in human,
could result in harmful phenotypes in cow, guinea pig
and cat, if mutated, due to their highly level of
sequential and positional (near the active site) similarity
in all the species. Similarly, E53, W77, R188, Y359, E563,
Q639 and R760 seem to be extremely conserved
throughout, thus mutations at these residues could
cause lethal genotypes/phenotypes in cow, guinea pig
and cat. It is also evident that R220 and F320, whose
substitution results in nil or extremely low enzyme
activity in cow, and R227 which when substituted causes
improper ligand binding in guinea pig, are conserved
across all the species thereby provoking the idea that
mutations involving these residues in human and cat
could prove to be severe. Due to the different mamma-
lian species represented here, all these positions can be
considered potential disease-causing mutations for all
mammals.
Besides the above disease-implicated mutations, other
structurally and functionally vital conserved residues
Figure 6
Mapping truncation mutations to the different chains
of the human a-mannosidase protein.T h ee x t e n to f
nonsense, insertion and deletion mutants are shown as red,
orange and green arrows, represent lethal, moderate and
mild phenotypes, respectively.
Figure 7
Conservation analysis of mutations across the four
species. Alignment of the wild-type sequences from all four
species shows a high level of sequence similarity, with
conserved (*), conservatively substituted (:) and semi-
conservatively substituted (.) residues. Sequence segments
known to be mutational hot-spots are shown. Sequence
names and numbers are from Swiss-Prot.
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Specifically, mutations in the residues comprising the
active site of the enzyme could have serious effects.
Figure 8 shows the Tris ligand, the zinc ion and all the
surrounding residues within the vicinity of 5 Å from the
ligand, which together form the active site of the
enzyme. Therefore, we predict that mutations involving
the residues D74, D196, F198, Y261, D319, W388,
H446, D447 and T452 (which are the active site
residues) can cause extremely compromised enzyme
activity and hence lead to severe genotypic and
phenotypic expressions. These residues are highly con-
served among all the species and are thus capable of
severe forms of a-mannosidosis in human, cow, guinea
pig and cat upon mutation. This residue set represents a
structurally-derived mutation hot-spot, which are other-
wise separated along the sequence of a-mannosidase.
Sequence-based mutational hot-spot regions in the
MAN2B1 gene
Mapping all the mutations onto the MAN2B1 gene
sequence revealed the scattering of mutations along the
length of the gene. It was also clear that the mutations
seemed to cluster in groups over segments of varying
sequence length called mutational hot-spot regions, all
through the gene. Upon closer investigation it was
evident that there were five distinct mutational hot-
spot regions with lengths varying from 117 to 606
nucleotides. Figure 9 is a pictorial representation of the
mutational mapping to the gene sequence, the nucleo-
tide range of each hot-spot and the concentration of the
Figure 8
Active site of bovine lysosomal a-mannosidase.T h e
Tris ligand (labeled Trs) is shown in orange, the Zn
2+ ion in
purple and all the active site residues in red (ball-and-stick
representation). These active site residues represent a
structural hot-spot region, for the lethal phenotype.
Figure 9
Location of all non-splicing mutations on the MAN2B1 gene sequence. Missense and nonsense mutations are shown
above the gene sequence, with the specific amino acid change indicated, while insertions and deletions are shown below the
gene sequence, numbered in terms of the bases affected. The grey areas represent sequence-derived mutational hot-spot
regions.
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coded for by the nucleotides within the range 961-1204
are most likely to undergo mutations due to the large
number of mutations found occurring within this range.
Residues from other hot-spots are also very likely to be
mutated. The hot-spots identified are from nucleotide
number 157-323, 562-679, 961-1204, 1383-1815 and
2140-2746. Due to the large number of nucleotides in
1383-1815 and 2140-2746 hot-spot regions the prob-
ability of occurrence of a mutational residue coded for
by these regions is high. It is also worth noting that the
occurrence of a harmful mutation is most likely to be
between 157-323, 562-679 and 961-1204 hot-spot
regions due to their close proximity to the active site.
Conclusion
Phenotypically, a-mannosidosis has a range of expres-
sion, with the most common manifestations including
mental retardation, hearing impairment, skeletal defor-
mities, and recurrent infections. Diagnosis relies on
demonstration of deficient a-mannosidase enzyme
activity in leukocytes or other nucleated cells such as
fibroblasts. From a clinical perspective, variation is
considerable, ranging from a severe infantile form that
includes profound mental retardation, hepatosplenome-
galy, severe dysostosis multiplex and early death to a
mild juvenile form that includes moderate mental
retardation, hearing impairment, milder dysostosis and
survival into adult life. The high phenotypic variability,
even between siblings with identical mutations, has so
far prevented adoption of a standardized clinical typing,
further complicating research into potential treatments.
This analysis establishes a significant correlation
between the genotype and the phenotype of the disease.
The feline 1748del4 mutation, which causes a severe
genotype and an equally fatal phenotype leading to the
destruction of the enzyme structure thereby rendering it
non-functional, is a good example of our derived
relationship. a-mannosidosis caused by this mutation
is fatal due to the absence of mannosidase activity in
the liver of the Persian cats. There are also missense
mutations like the bovine F320L, where the phenotype
(with only 0.3% of the normal levels of enzyme activity)
was as severe as the effect of the mutation on the
genotype of the enzyme. The effect of this mutation
cannot be explained by sequence analysis alone. Our
work suggests that the mutations in MAN2B1 gene are
scattered over the entire gene providing us with five
mutational hot-spot regions. This gives us an opportu-
nity to predict the degree of severity for a particular
mutation and also to predict the residues that are most
likely to undergo mutations based on their genotypic
location. Moreover, the high degree of mutational
heterogeneity of a-mannosidosis is comparable to that
observed in many other lysosomal disorders. Based on
the co-location of mutations from different organisms
(human, cow, guinea pig and cat) and their proximity to
the enzyme active site, we have extrapolated observed
mutations from one species to homologous positions in
other organisms, as a predictive approach for detecting
likely a-mannosidosis, based on orthologous positions
in the multiple sequence alignment of the a-mannosi-
dase sequences. Our investigation highlights the effect of
disease mutations on protein structure and forms the
basis for understanding the molecular determinants
for phenotypic variations. This study could play a vital
role in developing therapies for inherited diseases. Since
lysosomal a-mannosidase is an essential enzyme and all
observed mutations affect its functioning, our study
suggests that rather than drug/inhibitor design, this
disease could be tackled through gene therapy.
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